\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe official portal of the network of European Digital Innovation Hubs is now online.
The EDIH Network is currently comprised of 136 EDIHs that are co-funded by the European Commission´s Digital Europe Programme. Its core mission is to build up the digital capacities of SMEs and public sector organisations throughout the European Union. To accelerate digital transformation, the EDIH Network is focused on building capacity and leveraging cutting-edge technologies in key sectors in every European Union Member State.
This website is managed by the Digital Transformation Accelerator (DTA), which has the objective to foster networking, cooperation and knowledge transfer activities between EDIH, SME and mid-caps, the public sector and the other relevant stakeholders and initiatives.
The website gathers information on the EDIHs, the Network, EDIH support services and how to benefit from these services.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
